Page last updated: 2024-09-04

torcetrapib and Insulin Resistance

torcetrapib has been researched along with Insulin Resistance in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Briand, F; Costard, C; Muzotte, E; Prunet-Marcassus, B; Sordello, S; Sulpice, T; Thieblemont, Q	1
Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD	1
André, A; Briand, F; Ouguerram, K; Sulpice, T; Thieblemont, Q	1
Byrne, CD; Wild, S	1

Trials

1 trial(s) available for torcetrapib and Insulin Resistance

Article	Year
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation, 2011, Aug-02, Volume: 124, Issue:5 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines	2011

Article

Year

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Circulation, 2011, Aug-02, Volume: 124, Issue:5

Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines

2011

Other Studies

3 other study(ies) available for torcetrapib and Insulin Resistance

Article	Year
Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins E; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Deoxyglucose; Diet, Atherogenic; Disease Models, Animal; Drug Evaluation, Preclinical; Dyslipidemias; Enzyme Activation; Feces; Glucose; Homeostasis; Hyperglycemia; Insulin Resistance; Male; Mesocricetus; Muscle, Skeletal; Quinolines; Random Allocation; Species Specificity	2014
CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice. Clinical and translational science, 2011, Volume: 4, Issue:6 Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-100; Bile Acids and Salts; Biological Transport; Body Weight; Cells, Cultured; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Dyslipidemias; Humans; Insulin Resistance; Lipoproteins; Macrophages; Male; Mice; Mice, Transgenic; Obesity; Quinolines	2011
Time to rethink high-density lipoprotein? Heart (British Cardiac Society), 2008, Volume: 94, Issue:6 Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Insulin Resistance; Lipoproteins, HDL; Quinolines; Risk Reduction Behavior	2008